Home World News FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway Modulation-Naïve... World News FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer By Ogkologos - July 15, 2026 221 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism July 5, 2023 AI Model Identifies How Every Country Can Improve Its Cancer Outcomes January 14, 2026 ASCO Annual Meeting 2023: Radiation Therapy May Not Be Needed After... June 6, 2023 ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment... August 19, 2026 Load more HOT NEWS Coronavirus and cancer – July updates Transforming optimism: finding new ways to treat rare cancers Study Explores Jaw Problem Linked to Zoledronic Acid, Finds Risk Factors “Supporting research is mission critical for me and always will be”...
